Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease

Kidney International, Supplement

Volumn 56, Issue 71, 1999, Pages

  Attman, Per Ola ^a   Alaupovic, Petar ^b   Samuelsson, Ola ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Apolipoproteins; Dyslipidemia; Lipoproteins; Progressive renal disease; Renal failure

Indexed keywords

APOLIPOPROTEIN B; LIPOPROTEIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CHOLESTEROL; LIPID;

BLOOD; DISEASE COURSE; HUMAN; KIDNEY DISEASE; PATHOLOGY; REVIEW; RISK FACTOR; CONFERENCE PAPER; DYSLIPOPROTEINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NEPHROTIC SYNDROME; PRIORITY JOURNAL;

APOLIPOPROTEINS B; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; LIPOPROTEINS; RISK FACTORS; TRIGLYCERIDES;

EID: 0033050484     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988
2. HUNSICKER LG, ADLER S, CAGGIULA A, ENGLAND BK, GREENE T, KUSEK JW, ROGERS NL, TESCHAN PE: Predictors of the progression of renal disease in the modification of diet and in renal disease study. Kidney Int 51:1908-1919, 1997
3. ATTMAN P-O, SAMUELSSON O, ALAUPOVIC P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21:373-392, 1993
4. MOORHEAD JF, EL-NAHAS M, CHAN MK, VARGHESE Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 11:1309-1311, 1982
5. ATTMAN P-O, SAMUELSSON O, ALAUPOVIC P: Progression of renal failure: Role of apolipoprotein B-containing lipoproteins. Kidney Int 52(Suppl 63):S98-S101, 1997
6. WHEELER DC, BERNARD DB: Lipid abnormalities in the nephrotic syndrome: Causes, consequences and treatment. Am J Kidney Dis 23:331-346, 1994
7. ALAUPOVIC P: Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families. Prog Lipid Res 30:105-138, 1991
8. ATTMAN P-O, KNIGHT-GIBSON C, TAVELLA M, SAMUELSSON O, ALAUPOVIC P: Increased concentrations of apoB-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure. Miner Electrolyte Metab 18:199-202, 1992
9. SAMUELSSON O, ATTMAN P-O, KNIGHT-GIBSON C, LARSSON R, MULEC H, WEISS L, ALAUPOVIC P: Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 9:1482-1488, 1998
10. ATTMAN P-O, ALAUPOVIC P, TAVELLA M, KNIGHT-GIBSON C: Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 11:63-69, 1996
11. SAMUELSSON O, ATTMAN P-O, KNIGHT-GIBSON C, LARSSON R, MULEC H, WEDEL H, WEISS L, ALAUPOVIC P: Plasma levels of lipoprotein (a) do not predict progression of human chronic renal failure. Nephrol Dial Transplant 11:2237-2243, 1996
12. SAMUELSSON O, ATTMAN P-O, KNIGHT-GIBSON C, KRON B, LARSSON R, MULEC H, WEISS L, ALAUPOVIC P: Lipoprotein abnormalities without hyperlipidemia in moderate renal insufficiency. Nephrol Dial Transplant 9:1580-1585, 1994
13. KEANE WF, O'DONNEL MP, KASISKE BL, SCHMITZ PG: Lipids and the progression of renal disease. J Am Soc Nephrol 1:S69-S74, 1990
14. KEANE WF: Lipids and the kidney. Kidney Int 46:910-920, 1994
15. DIAMOND JR: Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 39(Suppl 31):S29-S34, 1991
16. KAMANNA VS, ROH DD, KIRSCHENBAUM MA: Atherogenic lipoproteins: Mediators of glomerular injury. Am J Nephrol 13:1-15,1993
17. MASCHIO G, OLDRIZZI L, RUGIU C, DE BBIASE V, LOSCHIAVO C: Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure. Kidney Int 39(Suppl 31):S70-S72, 1991
18. CAPPELLI P, EVANGELISTA M, BONOMINI M, PALMIERI PF, ALBER-TAZZI A: Lipids and the progression of chronic renal failure. Nephron 62:31-35, 1992
19. BAZZATO G, FRACASSO A, SCANFERLA F: Risk factors on the progression of diabetic nephropathy. Role of hyperlipidemia and its correction. Nephrol Dial Transplant 7:710, 1992
20. SAMUELSSON O, AURELL M, KNIGHT-GIBSON C, ALAUPOVIC P, ATTMAN P-O: Apolipoprotein B-containing lipoproteins and the progression of renal insufficiency. Nephron 63:279-285, 1993
21. SAMUELSSON O, MULEC H, KNIGHT-GIBSON C, ATTMAN P-O, KRON B, LARSSON R, WEISS L, WEDEL H, ALAUPOVIC P: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908-1915, 1997
22. HODIS HN, MACK WJ, AZEN SP, ALAUPOVIC P, POGODA JM, LABREE L, HEMPHILL L, KRAMSCH D, BLANKENHORN DH: Triglyceride-rich and cholesterol-rich lipoproteins have a differential effect on mild/ moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 90:42-49, 1993
23. ALAUPOVIC P, MACK WJ, KNIGHT-GIBSON C, HODIS HN: The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscl Thromb Vasc Biol 17:715-722, 1997
24. MASSY ZA, MA JZ, Louis TA, KASISKE BL: Lipid-lowering therapy in patients with renal disease. Kidney Int 48:188-198, 1995
25. SAMUELSSON O, ATTMAN P-O, KNIGHT-GIBSON C, KRON B, LARSSON R, MULEC H, WEISS L, ALAUPOVIC P: Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: A controlled study in human chronic renal disease. Nephron 75:286-294, 1997
26. th European Atherosclerosis Society Congress, Geneva, Switzerland, September 6-9, 1998